Recent Updates
Recently added Catalysts

Etrasimod

Phase 3

Ulcerative Colitis | Small molecule | Immunology |Pfizer, Inc.|Last Updated: Jun 8, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials9
Total Enrollment2,323
FDA Designations
No designations recorded
Clinical Trials (9)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03996369Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative ColitisPHASE3 COMPLETED 354Sep 1, 2020Dec 1, 2021Dec 20, 2022 -
NCT03945188Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative ColitisPHASE3 COMPLETED 433Jun 1, 2019Feb 1, 2022Dec 19, 2022 -
NCT04706793Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)PHASE3 COMPLETED 42Dec 25, 2020Aug 3, 2022Oct 16, 202338 Japan
NCT03950232An Extension Study for Treatment of Moderately to Severely Active Ulcerative ColitisPHASE3 ACTIVE NOT_RECRUITING 896Sep 5, 2019Jun 19, 2029May 11, 2026211 United States, Australia +29
NCT02536404Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative ColitisPHASE2 COMPLETED 118Jan 1, 2016Oct 1, 2018Nov 25, 2021 -
NCT02447302Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative ColitisPHASE2 COMPLETED 156Oct 1, 2015Feb 1, 2018Apr 4, 2021 -
NCT05287126A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative ColitisPHASE2 RECRUITING 36Dec 16, 2022Jul 10, 2033Jun 8, 202646 United States, Belgium +4
NCT05061446Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative ColitisPHASE2 COMPLETED 54Sep 10, 2021Oct 6, 2023Oct 29, 202480 Japan
NCT04607837Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative ColitisPHASE2 COMPLETED 234Apr 12, 2021Jun 19, 2024Jul 15, 2025288 United States, Australia +16
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of Participants Achieving Clinical Remission at Week 40 of Study APD334-308
Week 40 of APD334-308

Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

Number and Severity of Safety Measures
Up to approximately 8 years

Safety as assessed by the evaluation of adverse events

Proportion of Participants Achieving Clinical Remission as Assessed by Modified Mayo Score (MMS) at Week 52
Week 52
Percentage of Participants Who Achieved Clinical Remission at Week 12
Week 12

Clinical remission:Participants with stool frequency (SF)subscore=0(or of 1 with greater than or equal to(\>=)1 point decrease from baseline,rectal bleeding(RB)subscore=0 and endoscopic score(ES)less than or equal to(\<)=1(excluding friability).SF subscore:number of stools in 24-hours relative to normal number of stools for that participant in same period,score ranged from 0(normal number of stools) to 3(5 or more stools than normal),higher scores=more severity.RB subscore:most severe amount of blood passed per rectum in 24-hours,score ranged from 0(no blood seen)to 3(blood alone passes),higher scores=more severity.ES:reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy,score ranged from 0(normal or inactive disease) to 3(severe disease \[spontaneous bleeding,ulceration\]),higher scores=more severity.Modified Mayo score:measure disease activity for UC,score:0(normal) to 9(maximum severity),comprised subscores for SF,RB,ES.higher score=more severe disease activity.

Percentage of Participants Achieving Clinical Remission (CR) at Week 52 Using Modified Mayo Score (MMS)
Week 52

MMS is used to assess disease activity in participants with UC and has following components: endoscopic score(ES),rectal bleeding(RB),stool frequency(SF).Each component score ranges from 0 to 3(0=normal,1=mild,2=moderate,3=severe); higher scores indicating more severe disease.ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy,scores ranged from 0(normal or inactive disease) to 3(severe disease \[spontaneous bleeding, ulceration\]).RB reported most severe amount of blood passed per rectum in 24-hour period,scores ranged from 0(no blood seen) to 3(blood alone passes).SF reported number of stools in 24-hour period relative to normal number of stools for that participant in same period,scores ranged from 0(normal number of stools) to 3(5 or more stools than normal).CR per FDA draft guidance defined as:SF=0 or 1 and no greater than baseline, RB=0,ES less than or equal to (\<=)1(excluding friability).Percentage of participants achieving CR at Week 52 was evaluated.

Secondary Endpoints
Percentage of Participants Achieving Endoscopic Improvement at Week 40 of Study APD334-308
Week 40 of APD334-308
Percentage of Participants Achieving Symptomatic Remission at Week 40 of Study APD334-308
Week 40 of APD334-308
Percentage of Participants With Mucosal Healing at Week 40 of Study APD334-308
Week 40 of APD334-308
Unlock Study Endpoints
Study Design & Arms
Treatment Arms
ArmTypeDescription
Etrasimod 2 mgEXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -
EtrasimodEXPERIMENTAL -
Etrasimod Dose 1EXPERIMENTAL -
Etrasimod Dose 2EXPERIMENTAL -
Interventions
NameTypeDescription
EtrasimodDRUGEtrasimod 2 mg tablet by mouth, once daily up to 12-Week Induction Treatment Period
PlaceboDRUGEtrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period
Unlock Study Design Details
Eligibility Criteria
Age Range16 Years — 80 Years
SexALL

Inclusion Criteria: Participants with moderately to severely active ulcerative colitis (UC) are eligible to enroll into this study if they fulfill all of the following: * Must have completed the Week 12 visit of Study APD334-302 * Ability to provide written informed consent or assent (parent or le...

Countries:JapanUnited StatesAustraliaAustriaBelarusBelgiumBulgariaCzechiaEstoniaFranceGeorgiaGermanyHungaryIndiaIsraelItalyLatviaLebanonMexicoMoldovaPolandPortugalRomaniaRussiaSlovakiaSouth AfricaSouth KoreaSpainTurkey (Türkiye)UkraineUnited Kingdom
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJun 8, 2026NCT05287126lastUpdatePostDate: changed
MEDIUMMay 26, 2026NCT05287126primaryCompletionDate: changed
LOWMay 26, 2026NCT03950232primaryCompletionDate: changed
LOWMay 24, 2026NCT05287126studyFirstPostDate: changed
LOWMay 24, 2026NCT03950232studyFirstPostDate: changed